These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
899 related articles for article (PubMed ID: 27522556)
1. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database. Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556 [TBL] [Abstract][Full Text] [Related]
2. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686 [TBL] [Abstract][Full Text] [Related]
3. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441 [TBL] [Abstract][Full Text] [Related]
5. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388 [TBL] [Abstract][Full Text] [Related]
7. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P Oncology; 2015; 89(1):37-46. PubMed ID: 25766660 [TBL] [Abstract][Full Text] [Related]
8. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172 [TBL] [Abstract][Full Text] [Related]
10. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy? Hackert T; Ulrich A; Büchler MW Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331 [No Abstract] [Full Text] [Related]
11. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Yadav S; Xie H; Bin-Riaz I; Sharma P; Durani U; Goyal G; Borah B; Borad MJ; Smoot RL; Roberts LR; Go RS; McWilliams RR; Mahipal A Eur J Surg Oncol; 2019 Aug; 45(8):1432-1438. PubMed ID: 30914290 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841 [TBL] [Abstract][Full Text] [Related]
14. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786 [TBL] [Abstract][Full Text] [Related]
15. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211 [TBL] [Abstract][Full Text] [Related]
16. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma. Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417 [TBL] [Abstract][Full Text] [Related]
17. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208 [TBL] [Abstract][Full Text] [Related]
18. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy for resectable pancreatic cancer. Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939 [TBL] [Abstract][Full Text] [Related]
20. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review. Czosnyka NM; Borgert AJ; Smith TJ HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]